News & Events

Northern New England Clinical & Translational Research (NNE-CTR) successes, events and news.


Highlights

Funding, Fellowships & Opportunities (including COVID-19)

January 24, 2019 by Jennifer Smith

Click here for a curated and updated list of summaries of CTR-relevant opportunities.

Comprehensive Weekly NIH Listings: Current RFAs , Current Parent Announcements
institutes.
-----------------------------------------------------------------
COVID-19 related funding opportunities.  Also, NIH-related notices.
-----------------------------------------------------------------

NIDA is issuing this Notice of Special Interest (NOSI) NOT-DA-20-047 to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
Background
As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs’ effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder.

Deadlline: March 31, 2021

-----------------------------------------------------------------
NIGMS hopes to stimulate interest in sepsis research in communities that may not have been aware of the challenges of identifying and treating sepsis patients.  Sepsis research needs new investigators and new approaches to challenging questions of disease heterogeneity.
NOT GM 19-054 NIGMS Priorities for Sepsis Research and NOT GM 19-057 Strategies to Support Acquisition and Use of Biospecimens for Research on Sepsis in Humans have been released in response to recommendations from an advisory council working group on sepsis. Over the next 3-5 years NIGMS will be optimizing its research grant support of preclinical and clinical sepsis studies to most effectively provide fundamental knowledge of human sepsis.  Several specific topics of research interest that involve clinical studies, research organisms, data science and technology development are outlined in NOT GM 19-054.  In addition, two areas of low priority are described:

  • Studies using rodent models of sepsis unless uniquely well-justified in terms of potential for providing novel insights into human sepsis
  • Clinical trials: In general, NIGMS will only consider support of clinical trials that are designed to test strong mechanistic hypotheses and include appropriate patient stratification. NIGMS expects the scientific foundation of all clinical trial applications to be based on data from rigorously designed and controlled human studies that have been published in peer-reviewed literature. NIGMS is unlikely to support large-scale clinical trials unless other NIH institutes/centers or federal agencies provide joint support to optimize trial efficiency, recruitment, and oversight.

Please feel free to reach out to Sarah Dunsmore, the program director for the NIGMS sepsis research portfolio.  She will be glad to discuss NIGMS interests in sepsis research and current funding opportunities for sepsis research at NIGMS and other relevant NIH institutes.
-----------------------------------------------------------------

RFA-CA-19-034 Feasibility & Planning Studies for Development of SPOREs to Investigate Cancer Health Disparities (P20)

All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed.

All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees.  Due June 19, 2020 and October 18, 2020.

-----------------------------------------------------------------